Last reviewed · How we verify
NCT06124820: UTIEXTERMINATE
RCT Comparing Intravaginal Laser Therapy to Sham in Post-menopausal Women with Recurrent Urinary Tract Infections
NA trial testing Deka SmartXide Touch C60 (MonaLisa Touch) in Recurrent Urinary Tract Infection in 48 participants. Participants enrolled and being followed up; not accepting new ones.
8 October 2026
Quick facts
| Lead sponsor | King's College Hospital NHS Trust |
|---|---|
| Phase | NA |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 48 |
| Start date | 1 October 2023 |
| Primary completion | 8 October 2026 |
| Estimated completion | 8 October 2026 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- Deka SmartXide Touch C60 (MonaLisa Touch)
- Sham
Conditions studied
- Recurrent Urinary Tract Infection — all drugs for Recurrent Urinary Tract Infection →
- Genitourinary Syndrome of Menopause — all drugs for Genitourinary Syndrome of Menopause →
Sponsor
King's College Hospital NHS Trust
Who can join
Eligibility, female only, with Recurrent Urinary Tract Infection or Genitourinary Syndrome of Menopause. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Recurrent urinary tract infection (rUTI) is a common and difficult to treat problem with limited treatment option; postmenopausal women are disproportionately affected. The genitourinary syndrome of menopause (GSM) describes the broad spectrum of signs and symptoms caused by the loss of endogenous sex steroids. The combined effects of urogenital epithelial tissue thinning and changes to the vaginal and bladder microbiome can predispose to ascending UTIs. Recurrent UTIs is a component of GSM. Intravaginal laser therapy has been shown to be safe and effective for the treatment of GSM, however, the role of laser for treatment of recurrent UTIs is unknown. We hypothesis that the incidence of UTI will be reduced as CO2 laser restores vaginal epithelium to a state similar to that of a pre-menopausal woman, preventing microtrauma, and increases Lactobacillus and normal flora (Athanasiou et al., 2016). Lactobacillus is considered the bacteria that helps keep the vagina healthy and infection free through its production of lactic acid which lowers vaginal pH, this more acidic environment may be protective from uropathogens. We therefore aim to conduct a single-blinded, multi-centre, randomised controlled trial comparing the use of intravaginal CO2 laser therapy to sham in post-menopausal women with rUTIs and to determine the impact on the microbiome.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06124820
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Recurrent Urinary Tract Infection
Currently open trials in the same condition.
- NCT06940622 — A Trial of D-mannose for the Prophylaxis of Recurrent Urinary Tract Infections · NA · recruiting
- NCT06050148 — Faecal Microbiota Transplantation as Means of Preventing Recurrent Urinary Tract Infections · Phase 2, PHASE3 · recruiting
- NCT05553652 — The Effect of ASTARTE™ on Recurrent Urinary Tract Infection · NA · recruiting
- NCT04807894 — Prevention of Recurrent UTI Using Vaginal Testosterone Versus Placebo Placebo · Phase 4 · recruiting
Other King's College Hospital NHS Trust trials
Trials by the same sponsor.
- NCT07384884 — Surgery and Laser Interstitial Thermal Therapy for Bilateral Glioblastomas · NA · not yet recruiting
- NCT07379723 — Brief Intervention for FCD: A Feasibility Study · NA · recruiting
- NCT07062731 — Pelvic Floor Exercises for Suboptimal Anorectal Manometry · recruiting
- NCT06766162 — Virtual Reality to Improve Patient Experience During Endoscopic Mucosal and Submucosal Resection · NA · completed
- NCT06918756 — Development of a Cough Control Questionnaire (CCQ) · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06124820 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by King's College Hospital NHS Trust
- Last refreshed: 10 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06124820.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing